Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238467 · ClinicalTrials.gov registry record
Immunological Responses of COVID-19 Vaccination
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 42
- Enrollment target
NCT05238467 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 42 participants.
The verdict
NCT05238467 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
Cancer patients with COVID-19 have a 30% higher mortality rate compared to the general population and are considered a high-risk group by the American Association for Cancer Research that should be given "high priority" during COVID-19 vaccine administration. Although studies have suggested that vaccination during active treatment with chemo and/or radiation therapy provides suboptimal antibody response, the studies were underpowered and heterogeneous thus putting this conclusion into question. We need data in cancer patients on immunosuppressive chemotherapy at the time of COVID vaccination to understand how immune responses compare to healthy controls and cancer patients not on immunosuppressive therapy.
Interventions
- OTHER COVID antibody titers in the blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2023-02-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05238467
The ClinicalTrials.gov registry entry for NCT05238467 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COVID antibody titers in the blood is the first listed.
NCT05238467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05238467 about?
NCT05238467 is a clinical study titled "Immunological Responses of COVID-19 Vaccination". Cancer patients with COVID-19 have a 30% higher mortality rate compared to the general population and are considered a high-risk group by the American Association for Cancer Research that should be given "high priority" during COVID-19 vaccine administration. Although studies have suggested that vac...
What is the current status of trial NCT05238467?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2021-05-21. Estimated completion is 2023-02-13.
What interventions are being tested in trial NCT05238467?
The interventions under investigation include: COVID antibody titers in the blood (OTHER).
Who is sponsoring clinical trial NCT05238467?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.